Wataru Sasaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wataru Sasaki has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Akio Tanaka
Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
2 shared publications - Ryo Saito
Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
2 shared publications - Akihiko Uchiyama
Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan
1 shared publication - Daisuke Watanabe
Department of Dermatology Aichi Medical University Aichi Japan
1 shared publication Haruka Watanabe
Department of Dermatology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
1 shared publication- Hirofumi Kamada
Department of Dermatology Iwate Medical University Iwate Japan
1 shared publication
Latest Publications
- Open Access
- 11 June 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (8) , 1179-1183
Extended‐Interval Dosing and Discontinuation of Dupilumab in Atopic Dermatitis: A Real‐World Retrospective Study
This retrospective study evaluated the clinical courses and treatment patterns of 81 patients with atopic dermatitis (AD) treated with dupilumab at Hiroshima University Hospital. Patients were categorized into six groups based on their clinical outcomes, including those who continued treatment, achieved remission and discontinued, or discontinued due to adverse effects or insufficient efficacy. Of the 81 patients, 38 (47%) continued treatment throughout the study period, and 16 (20%) achieved remission and discontinued treatment without relapse. Analysis of baseline severity using EASI and TARC levels revealed no significant differences between these groups, suggesting that baseline severity does not predict long‐term therapeutic outcomes. Regarding concomitant topical therapy, although the potency of topical corticosteroids (TCS) remained unchanged in most patients, the total dosage was significantly reduced by a mean of 71.3%, reflecting a successful transition to proactive therapy or a reduced affected body surface area. Furthermore, this study investigated the feasibility of extending dupilumab dosing intervals. Nearly half of the patients extended their intervals including every 3 weeks (Q3W), Q4W, and up to Q8W by 6 months without exacerbation. By 12 months, 22 of the 40 evaluable patients successfully transitioned to extended intervals up to Q12W. These findings suggest that baseline disease severity does not necessarily predict the long‐term clinical course of dupilumab therapy in patients with AD. Although TCS potency is often maintained to ensure stability, the dosage can be drastically reduced. Furthermore, a subset of patients can discontinue or extend the dosing intervals, and the optimal timing for extending intervals is more flexible and can be initiated earlier than currently suggested by previous reports.
- 11 June 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (8) , 1179-1183
Open AccessExtended‐Interval Dosing and Discontinuation of Dupilumab in Atopic Dermatitis: A Real‐World Retrospective Study
This retrospective study evaluated the clinical courses and treatment patterns of 81 patients with atopic dermatitis (AD) treated with dupilumab at Hiroshima University Hospital. Patients were categorized into six groups based on their clinical outcomes, including those who continued treatment, achieved remission and discontinued, or discontinued due to adverse effects or insufficient efficacy. Of the 81 patients, 38 (47%) continued treatment throughout the study period, and 16 (20%) achieved remission and discontinued treatment without relapse. Analysis of baseline severity using EASI and TARC levels revealed no significant differences between these groups, suggesting that baseline severity does not predict long‐term therapeutic outcomes. Regarding concomitant topical therapy, although the potency of topical corticosteroids (TCS) remained unchanged in most patients, the total dosage was significantly reduced by a mean of 71.3%, reflecting a successful transition to proactive therapy or a reduced affected body surface area. Furthermore, this study investigated the feasibility of extending dupilumab dosing intervals. Nearly half of the patients extended their intervals including every 3 weeks (Q3W), Q4W, and up to Q8W by 6 months without exacerbation. By 12 months, 22 of the 40 evaluable patients successfully transitioned to extended intervals up to Q12W. These findings suggest that baseline disease severity does not necessarily predict the long‐term clinical course of dupilumab therapy in patients with AD. Although TCS potency is often maintained to ensure stability, the dosage can be drastically reduced. Furthermore, a subset of patients can discontinue or extend the dosing intervals, and the optimal timing for extending intervals is more flexible and can be initiated earlier than currently suggested by previous reports.
- Open Access
- 23 July 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (3) , 399-409
Clinical Characteristics and Risk Factors for Cutaneous Manifestations Associated With Nemolizumab in Atopic Dermatitis: A Multicenter Retrospective Study in Japan
Nemolizumab, an anti‐interleukin‐31 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)‐associated pruritus. While it is effective for itch control, nemolizumab‐associated cutaneous adverse events have been increasingly recognized, yet their clinical features remain poorly characterized. In this study, we aimed to investigate the incidence, clinical characteristics, and timing of cutaneous manifestations associated with nemolizumab treatment in patients with AD, and to explore potential associations with baseline disease severity and immunological parameters. We conducted a multicenter retrospective study involving 219 patients aged ≥ 13 years with AD who received nemolizumab at 13 institutions in Japan between August 2022 and February 2024. Cutaneous eruptions were classified into six categories based on clinical consensus. Patients who received fewer than three doses without developing skin reactions were excluded. Clinical and laboratory parameters were compared between patients with and without cutaneous manifestations. Cutaneous manifestations occurred in 88 patients (40.2%), most commonly within the first three doses. Erythema was the most frequent presentation (69.3%), and 62.5% of eruptions were non‐pruritic. No significant associations were observed between the occurrence of skin reactions and baseline eczema area and severity index scores, eosinophil counts, serum immunoglobulin E, or thymus and activation‐regulated chemokine levels. Two cases of bullous pemphigoid were identified. Despite topical corticosteroid treatment, nemolizumab therapy was discontinued in 42% of the patients affected. In conclusion, nemolizumab frequently induces early‐onset, morphologically distinct cutaneous eruptions that appear to be independent of baseline disease severity or biomarkers.
- 23 July 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (3) , 399-409
Open AccessClinical Characteristics and Risk Factors for Cutaneous Manifestations Associated With Nemolizumab in Atopic Dermatitis: A Multicenter Retrospective Study in Japan
Nemolizumab, an anti‐interleukin‐31 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)‐associated pruritus. While it is effective for itch control, nemolizumab‐associated cutaneous adverse events have been increasingly recognized, yet their clinical features remain poorly characterized. In this study, we aimed to investigate the incidence, clinical characteristics, and timing of cutaneous manifestations associated with nemolizumab treatment in patients with AD, and to explore potential associations with baseline disease severity and immunological parameters. We conducted a multicenter retrospective study involving 219 patients aged ≥ 13 years with AD who received nemolizumab at 13 institutions in Japan between August 2022 and February 2024. Cutaneous eruptions were classified into six categories based on clinical consensus. Patients who received fewer than three doses without developing skin reactions were excluded. Clinical and laboratory parameters were compared between patients with and without cutaneous manifestations. Cutaneous manifestations occurred in 88 patients (40.2%), most commonly within the first three doses. Erythema was the most frequent presentation (69.3%), and 62.5% of eruptions were non‐pruritic. No significant associations were observed between the occurrence of skin reactions and baseline eczema area and severity index scores, eosinophil counts, serum immunoglobulin E, or thymus and activation‐regulated chemokine levels. Two cases of bullous pemphigoid were identified. Despite topical corticosteroid treatment, nemolizumab therapy was discontinued in 42% of the patients affected. In conclusion, nemolizumab frequently induces early‐onset, morphologically distinct cutaneous eruptions that appear to be independent of baseline disease severity or biomarkers.